Skip to content

Clinical Study on the Therapeutic Efficacy of Modified Xuanbai Chengqi Decoction in ARDS Patients Based on Bedside Hyperosmolar Saline Lung Perfusion Electrical Impedance Tomography

Clinical Study on the Therapeutic Efficacy of Modified Xuanbai Chengqi Decoction in ARDS Patients Based on Bedside Hyperosmolar Saline Lung Perfusion Electrical Impedance Tomography

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001163
Enrollment
Unknown
Registered
2025-06-12
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS

Interventions

Treatment group:On the basis of basic treatment, Modified Xuanbai Chengqi Decoction was administered.
Control group:Basic treatment: All patients received conventional treatment and comprehensive ICU care after enrollment including the treatment of the primary disease as well as respiratory support an

Sponsors

Chongqing hospital of traditional Chinese medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
19 Years to 79 Years

Inclusion criteria

Inclusion criteria: (1) It met the diagnostic criteria for ARDS in the 2012 Berlin definition (excluding hypoxemia caused by cardiogenic factor volume overload administration of PEEP >5cmH2O under mechanical ventilation oxygenation index <300mmHg) (2) Invasive mechanical ventilation treatment is required; (3) Be over 18 years old but under 80 years old; (4) The patient or their family members are willing to sign the informed consent form and participate in the researcher.

Exclusion criteria

Exclusion criteria: (1) Severe obesity with BMI>40Kg/m ²; (2) There are contraindications for the use of EIT (such as large-scale dressing coverage of the chest wall after thoracic surgery implantation of cardiac pacemakers implantation of in vivo automatic defibrillators thoracic deformity and large-scale skin injury of the chest wall); (3) Terminal stage of tumors and other diseases; (4) The expected survival time is less than 48 hours; (5) Pregnant and lactating women; (6) Patients with neuromuscular diseases; (7) Where informed consent is lacking or the patient is uncooperative or uncooperative;

Design outcomes

Primary

MeasureTime frame
Ventilation/Perfusion (V/Q) Matching Images;Pulmonary blood flow distribution image;Image of lung ventilation distribution;

Secondary

MeasureTime frame
Mechanical ventilation time in ICU;Length of ICU Stay;Weaning Success Rate from Mechanical Ventilation;APACHE II score at transfer out of the ICU or discharge;

Countries

China

Contacts

Public ContactYuling Zhou

Chongqing hospital of traditional Chinese medicine

18008333553@163.com+86 180 0833 3553

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026